Exploring the genome-wide impact of estrogen receptor alpha and estrogen receptor beta in breast and colon cancer cells by Edvardsson, Karin
  
 
 
From the Department of Biosciences and Nutrition 
Karolinska Institutet, Stockholm, Sweden 
 
Exploring the Genome-Wide Impact 
of Estrogen Receptor Alpha and 
Estrogen Receptor Beta in Breast 
and Colon Cancer Cells 
 
 
Karin Edvardsson 
 
 
 
 
Stockholm 2011 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover figure by Dr Ron Smith of Molecular Endocrinology (2011), 25(6):897-1074, from 
the article in the same issue by Edvardsson et al., 969–979. 
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by Universitetsservice US-AB, Solna, Sweden 
 
© Karin Edvardsson, 2011 
ISBN 978-91-7457-573-6 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
In memoriam, 
Mormor Ruth 
 
  
  
  
ABSTRACT 
Estrogen signaling is involved in the development and progression of breast cancer and 
is implicated to be protective in colon cancer. Estrogenic actions are conveyed through 
transcriptional regulation by ligand stimulated estrogen receptors (ERα and ERβ). ERα 
is upregulated in most breast cancers and is responsible for the proliferative effect of 
estrogen. ERβ on the other hand is usually downregulated, and studies indicate an 
antiproliferative function. Therapies targeting ERα are available and commonly used in 
the treatment of breast cancer. In the normal colonic epithelia, however, ERβ is the 
most abundant estrogen receptor and the suggested mediator of the protective effects of 
estrogen in colon cancer.  The role of ERβ in breast cancer and colon cancer is not well 
understood. Thus, exploring the genome-wide impact and contribution of both 
receptors in estrogen responsive cancers would substantially help to identify novel 
therapeutic and preventive strategies for these cancers. 
  
In Paper 1, we examined differences in transcriptional regulation between ERα and 
ERβ in the breast cancer cell line T47D. We could show that ERβ often exhibited an 
opposing effect on ERα-regulated genes within proliferation and regulation of cell 
cycle. We also demonstrated a set of genes only regulated by ERβ, indicating that, 
despite the high homology between the two receptors, there are differences in their 
transcriptional targets. The fact that ERβ opposed ERα indicates that ERβ activation 
may be of value in the treatment of breast cancer. To further explore the transcriptional 
role of ERα in breast cancer, we performed large-scale analyses of microRNA in 24 
hours estrogen treated ERα-expressing T47D cells, Paper II. However, we found no 
evidence of direct and rapid regulation of mature miRNAs by ERα. 
 
In Paper III, we studied ERβ gene regulation in colon cancer cells. We could show 
that ERβ-expressing xenografts grew significantly slower than those lacking ERβ. 
Further we demonstrated that ERβ induced a transcriptional response independently of 
ERα and induced inhibition of the proto-oncogene MYC and other G1-phase cell cycle 
genes. In Paper IV, we dissected the regulatory networks of ERβ-induced 
transcriptional changes in human colon cancer cells. The set of genes changed by ERβ 
varied in different colon cancer cell lines, however, corresponded to the same 
biological processes such as cell cycle regulation and kinase activity. In addition, we 
identified the ERβ-driven downregulation of the transcription factor PROX1 as a key 
mechanism behind a large proportion of the transcriptional changes. In Paper V, we 
studied the effect of long term expression of ERβ on the miRNA pool in SW480 colon 
cancer cells. While we could not show a direct and rapid effect of ERα on the 
miRNome, we showed that long term expression of ERβ did induce large changes in 
the miRNA pool in colon cancer cells. In particular, we found the oncogenic           
miR-17-92 cluster to be downregulated and proposed this to be a consequence of the 
ERβ-induced downregulation of MYC.   
 
In conclusion, we have shown that ERβ is antiproliferative in breast and colon cancer 
cells, both when co-expressed with ERα and alone, as well as identified key signaling 
pathways. We suggest that activation of ERβ will have a beneficial effect for treatment 
or prevention of estrogen dependent cancers.  
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1 INTRODUCTION 
 
 
1.1 NUCLEAR RECEPTORS 
Nuclear receptors (NR) belong to a class of evolutionary conserved transcription 
factors. Generally, regulation of gene transcription occurs when a ligand, such as 
thyroid and steroid hormones or free fatty acids, binds to the receptor thus driving it to 
undergo conformational change leading to its activation. NRs regulate gene 
transcription involved in a wide array of biological processes, such as metabolism, 
development and reproduction. Therefore, deregulation in NR signaling has immense 
consequences in diseases such as diabetes, obesity, inflammation and cancer.   
 
 
1.1.1 Structural and functional organization 
The NRs share a similar structure containing a N-terminal region, a DNA-binding 
domain (DBD), a hinge region, a ligand-binding domain (LBD) and a short C-terminal 
domain (Figure 1) (126).  
 
 
Fig 1. General structural organization of NR consists of five domains named A-F. The A/B domain 
contains a section important for cofactor interaction, the C domain contains the DNA-binding domain, 
the D domain contains the hinge connecting DBD with LBD, and is also the target for different post-
translational modifications and the E domain contains the ligand binding domain and is also important for 
cofactor interactions. The function of the F domain is not fully understood. 
 
The N-terminal A/B region varies both in length and sequence between different NRs 
and contains, for the majority of NRs, a transcriptional activation domain known as 
AF-1. AF-1 is important for interaction with coregulatory proteins as well as for ligand-
independent transcriptional activity. The DBD is responsible for the binding to specific 
DNA sequences. Several residues, amongst others two zink-finger domains, build up 
the core of the DBD; two α-helices. The first helix contains the P-box, the residues 
critical for interaction with the two DNA half sites, while the second α-helix stabilizes 
the DBD structure (D-box) (4).  
 
Initially, it was believed that the primary purpose of the hinge was to serve as a linker 
between the DBD and the LBD. However, several studies have now shown that the 
hinge may change the receptor function through providing interaction surfaces for 
cofactors and/or post-translational modifications such as SUMOylation (205). The 
ligand-binding domain contains the ligand-binding pocket and a ligand-dependent 
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activation function domain (AF-2). AF-2 is necessary for recruitment of a variety of 
coactivating proteins.  
 
Both the size and shape of the binding-pocket as well as the hydrophobic/hydrophilic 
nature of the pocket surface correlates with ligand specificity of the receptor (33, 240, 
260). The steroid receptors GR, AR, PR, and ER have smaller volumes within their 
binding pockets compared to other NRs, as well as specific polar side chains of the 
pocket surface, which provides them with a high affinity towards a small number of 
ligands. Some of the adopted orphan receptors exhibit a larger volume binding-pocket 
compared to the steroid receptors, giving them the possibility to interact with a large 
number of ligands with different structures and of different sizes (159).  
 
 
1.1.2 A superfamily subdivided into three classes 
The NRs can be classified in different ways. Sequence alignment and phylogenetic tree 
construction reveals six evolutionary groups based solely on sequence homology (92). 
The NRs can also be divided into three classes based on the type of ligand they bind 
and/or where they are found in the unliganded state (20). Class I is known as the steroid 
receptor family, binds to steroids (estrogens, glucocorticoids, progestins, androgens, 
mineralocorticoids) and includes the estrogen receptor (ER), glucocorticoid receptor 
(GR), progesterone receptor (PR), androgen receptor (AR) and mineralocorticoid 
receptor (MR) (169). Class II is known as the thyroid/retinoid family, which binds to 
non-steroids (thyroid hormone, retinoids, prostaglandines) (20) and includes the thyroid 
receptor (TR), retinoic acid receptor (RAR), vitamin D receptor (VDR) and peroxisome 
proliferation-activated receptor (PPAR). The third class is a group of receptors to which 
no known ligands have been found (true orphans) or just recently been found (adopted 
orphans).  
 
Generally, unliganded class I receptors can be found in complex with heat shock 
proteins in the cytoplasm. Upon ligand binding, the receptor undergoes a 
conformational change leading to dissociation from the heat shock proteins and 
translocation to the nucleus where the activated receptor can bind to its response 
element (RE) and activate transcription of a gene. Unliganded receptors from group II 
are most commonly found associated with corepressors at their RE (in the nucleus) 
consequently leading to a repression of activation. Ligand binding results in 
conformational changes leading to dissociation of corepressors, recruitment of 
coactivators and thereby transcription of a gene (4). Recent studies have shown that 
unliganded class I receptors shuttles between the cytoplasm and the nucleus (173), 
however it has not been fully established if they have the same ability as class II 
receptors by binding to RE in the unliganded form. 
 
Class I receptors bind as homodimers to two hexanucleotide half sites, organized as 
inverted repeats often upstream of the promoter site, separated by a 3bp spacer. Class II 
receptors and some of the orphan receptors form heterodimers with the retinoid X 
receptor (RXR) and bind to two direct repeats of the consensus half site sequence 
separated by 1-5 bp spacer (169). 
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1.2 ESTROGEN RECEPTORS 
Almost 50 years ago it was discovered that estrogen signaling was mediated through a 
specific high-affinity receptor (132). This estrogen receptor (ER) was one of the first 
NRs to be cloned in 1986 (97, 98). A second estrogen receptor was identified ten years 
later, in 1996, (151) and the two receptors received their names estrogen receptor alpha 
(ER; NR3A1; ESR1) and estrogen receptor beta (ER; NR3A2; ESR2), respectively. 
The two ERs are highly homologous in their DNA binding domain, with approximately 
97% identical amino acid sequence, and in their ligand-binding domain where they 
have 56% similarity. However, they only have 24% identity in the N-terminus where 
the AF-1 domain is found (61).  
 
The two ERs are found expressed in various tissues and cells throughout the body. 
However, ERα and ERβ exhibit different tissue- and cell-type specific expression, 
sometimes both may be present in the same tissue but in different cell types. ERα can, 
for instance, be found in the uterus, kidney, prostate, testes, bone, mammary gland, 
placenta, ovary, liver, certain regions of the brain and white adipose tissue (53, 61, 
245). ERβ can be found in the ovary (granulosa cells), mammary gland, testis, colon, 
prostate, lung, bladder, bone marrow and certain regions of the brain (53, 61, 75, 245). 
 
The ERs are functionally unique amongst class I receptors since they can function both 
as homodimers as well as heterodimers (200).  Both receptors can bind to the DNA 
through the classical estrogen response element (ERE) GGTCAnnnTGACC, and they 
are both activated by the ligand 17β-estradiol. Still, activation of the two receptors 
triggers different responses. When they are co-expressed, ER often appears to exhibit 
an inhibitory action and oppose the effect of ER (175, 193). In addition, ER 
homodimers and ER heterodimers give rise to different sets of regulated genes (196, 
252). Differences in the LBD and AF-1domain, and thereby differences in cofactor 
interactions, can be the reasons to the various responses from the receptors.  
 
  
1.2.1 Ligands 
Estrogen is a steroid hormone and is, as all steroid hormones, derived from cholesterol. 
Figure 2 illustrates the biosynthesis of estrogens (148, 188). Even though estrogen is 
considered to be a female sex hormone, it also plays an important role in development 
of male sex characteristics. Both male ER knock-out mice, and mice lacking the 
enzyme used in estrogen production have impaired fertility, indicating a role for 
estrogen in sperm maturation (69, 213). 
 
17β-estradiol (E2) is a natural non-selective ligand for ERα and ERβ and is the most 
potent ER ligand, followed by the two metabolites estrone (E1) and estriol (E3). The 
last step in the steroid biosynthesis of estrogen involves aromatization of androgen and 
testosterone to estrone and estradiol with the enzyme aromatase cytochrome P450 
(222). The main source of production of estrogens in the premenopausal woman is the 
granula cells in the ovaries. In men and in postmenopausal women, estrogen is also 
produced at extragonadal sites in mesenchymal cells, in adipose tissue, osteoblasts and 
in the brain. In men, estrogens are also produced in the testis (221, 222). 
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Fig 2. Cholesterol is the first step in steroid biosynthesis. Several enzymes catalyze the different products 
into different steroids such as glucocorticoids, mineralocorticoids, androgens and estrogens.   
 
In addition to the natural ligands, there are several synthetic compounds able to 
function as agonist and/or antagonist on the two ERs. For instance, the synthetic 
compound ICI 182 780 (fulvestrant) is a pure antiestrogen for ERα in the sense that it 
reduces ERα protein levels in a dose dependent manner (62). Tamoxifen is a selective 
estrogen receptor modulator (SERM) that acts on both of the ERs but gives different 
response in various tissues. Its active metabolite, 4-hydroxytamoxifen, is a pure 
antagonist for ERβ and for ERα in breast tissue but an agonist for ERα in bone and 
uterus (167, 201). 
 
After ligand binding, an important α-helix in the C-terminus, α-helix 12, undergoes a 
reposition, thereby affecting the ability of AF-2 to bind to coregulators. For example, 
antagonist bound to ERα will reposition helix 12 so that it overlaps with the coactivator 
binding sites thus preventing binding of coactivators and consequently prevents 
transcriptional activity (218). A ligand (agonist or antagonist) may inhibit one or both 
AF domains. Since the N-terminus AF-1 differs between ERα and ERβ, an antagonist-
   5 
driven reposition of helix 12 may reduce transcriptional activity differently in the two 
ERs depending on if helix 12 occludes the coactivator recognition groove or not. 
 
 
1.2.2 Transcriptional regulation by estrogen receptors  
Transcriptional regulation by the two estrogen receptors may occur through several 
different pathways, see Figure 3 (32, 118). The classical estrogen signaling pathway 
occurs when liganded ER dimerizes and either binds directly to an ERE or to other 
response elements through tethering to other transcription factors such as AP-1 or SP1. 
In addition to the genomic regulation, there is also a rapid non-genomic regulation 
where a signal cascade is activated, following activation of secondary messengers 
(183). The non-genomic ER activation is too rapid to involve activation by mRNA or 
synthesis of protein. Instead, this often involves activation of various protein-kinase 
cascades. An example is ER activation of endothelial nitric oxide synthase through 
protein kinase-mediated phosphorylation (44). The fourth way of estrogen receptor 
activation includes ligand-independent posttranslational modifications such as 
phosphorylation, SUMOylation, methylation and acetylation of the estrogen receptor 
(19, 92, 138, 233). The different ways of transcriptional regulation by the ERs result in 
varying outcomes; e.g. different sets of genes can be regulated by liganded ERβ and 
unliganded ERβ (252).  
 
The ERE is a cis-regulatory element. Whilst it can be found less than 10 kb upstream of 
estrogen regulated genes, it is estimated that half of all conserved non-coding elements 
in vertebrates are >250 kb away from their associated genes (242). Theories on how 
distal binding sites physically can participate in transcriptional regulation suggest that it 
may be through coregulator recruitment to the target promoters via DNA looping (39, 
42). Many estrogen responsive genes have both proximal and distal binding sites (43, 
124, 160). Actually, only a small faction (5%) of ERα binding sites are located < 5 kb 
upstream of transcription start site (TSS) of the closest gene while 38% maps to 
intronic regions and 23% are within 100 kb from 5‟ start site and 19% are within 100 
kb of the 3‟ polyadenylation site (160). This indicates that ERα can regulate 
transcription through DNA interactions both proximal and distal of the TSS, not limited 
to orientation (5‟ or 3‟). Most ChIP studies have been performed in ERα-expressing 
MCF7 cells and since the ERs have high homology in their DNA binding domain it has 
been assumed that these binding sites also are true for ERβ. There are no known ERβ-
expressing breast cancer cell lines, therefore ERβ binding studies have been performed 
by overexpression of ERβ in MCF7 cells. These studies have confirmed that the ERα 
pattern with distal and proximal binding sites also is true for ERβ binding sites, in 
which only 3% of all ERβ binding sites are within 1kb from either end of a gene (259). 
Further, a substantial overlap of DNA binding sites between the two liganded receptors 
has been identified (47, 100).  
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Fig 3. Different mechanisms of ER action. 1, 2 and 4 illustrate the genomic action while 3 illustrates 
the non-genomic action. 1) Estrogen binds to ER. The receptor dimerizes and binds to estrogen 
response elements (ERE). 2) Ligand/ER tethers to other transcription factors such as c-Fos/c-Jun which 
in turn binds to respective response element (AP-1/SP1). 3) Ligand activated membrane bound ER in 
complex with other factors activates non-genomic signaling cascades. 4) Several different activated 
cascades lead to phosphorylation of ER which binds to ERE and results in ligand independent 
transcription. 
  
Transcriptional regulation by the ERs also involves recruitment of coregulators, histone 
deacetyltransferases (HDACs) and histone acetyltransferases (HATs) (108). 
Coregulators function as either coactivators or corepressors. Coactivators (e.g. SRC-1, 
SRC-2, SRC-3)  activate transcriptional regulation (141) and the first ones believed to 
be recruited to activated ERs are the p160 family of proteins and p300 (92). 
Corepressors (e.g. NCoR, SMRT) on the other hand decrease transcription (153). The 
coactivators have HAT activity while corepressors mediate HDAC activity (104, 246, 
253, 261). NCoR and SMRT does not themselves have enzymatic activities but rather 
resides in/or recruits transcriptional complexes that contain specific HDACs (92, 111). 
In addition, the retinoic acid receptor α (RARα) can associate with the ERs to maintain 
ER cofactor interactions, although it is not needed for ER recruitment to DNA (214).   
 
ERα transcriptional profiles in breast cancer cells, predominantly MCF7 cells, have 
been established, with several accepted estrogen stimulated ERα regulated genes such 
as pS2, SIAH2, GREB1, BCL2 and MYC (45, 89). Even though the ERs have high 
homology in the DNA binding domain, they still give rise to different transcriptional 
profiles. This has been illustrated in transcriptional studies in MCF7 cells and U2OS 
osteosarcoma cells with ERα and ERβ expression in which only 25% and 23% of all 
ERβ regulated genes were shared with ERα, respectively (100, 232).  One problem 
when studying ERβ transcriptional regulations in cancer cells is that there are no cancer 
cell lines endogenously expressing significant levels of ERβ. The few studies published 
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on ERβ transcriptional regulation have poor correlation, possibly caused by different 
techniques for introduction of ERβ as well as varying expression levels of the protein. 
Therefore, there is no general accepted transcriptional profile for ERβ in neither breast 
nor colon cancer cells. One study with ERβ overexpression in U2OS osteosarcoma 
cells have suggested that ERβ gene regulation can be divided into three classes: class I 
which is primarily regulated by unliganded ERβ, class II which is regulated only with 
E2 and class III which is regulated both by unliganded and liganded ERβ. Interestingly, 
AP-1 binding sites are more enriches in class I genes whereas ERE, SP1 and NFB1 
are enriched in class II genes, suggesting that ERβ regulates different sets of genes 
through interaction with different transcription factors and coregulators (252). 
However, this has not been confirmed in other cell lines and further studies are needed 
to define and confirm ERβ‟s transcriptional profile in different cell types. 
 
 
1.3 microRNA  
1.3.1 miRNAs regulate gene transcription 
MicroRNAs, miRNAs, were discovered about 20 years ago (155, 249), but their gene 
regulatory properties were not understood until about seven years ago (208). miRNAs 
are short (19-25 nt) single stranded non-coding RNA molecules. They suppress gene 
regulation through complementary binding between the miRNA 5' sequence and the 3' 
UTR of the target mRNA thereby mediating mRNA degradation and/or gene 
translation suppression. The target section of the mRNA can occasionally be located in 
the coding region. The miRNA 5' sequence is known as the 'seed' sequence. The seed 
consists of nucleotides 2-7 and is the most important part needed in miRNA target 
recognition (26).   
 
The miRNAs are highly conserved amongst species, e.g.  the miRNA Let-7 is identical 
between human, fly and C. elegans (198). Some miRNAs, however, are specific to 
primates only. Many of the primate specific miRNA are expressed in placenta, brain, 
testis and epididymis, and some are enriched in human embryonic cells. However, most 
of the primate specific miRNAs are expressed at low levels in adult tissues compared to 
embryonic cells, indicating a specific role in reproduction and embryonic development 
of primates (162). Human, mouse, zebrafish and fruit fly all have approximately the 
same sized genome. This tells us that other factors are important when it comes to the 
complexity of the animal. Animals with a more simple body plan tend to have a smaller 
miRNome., e.g. the human genome has 1424 miRNA genes, mouse 720, zebrafish 358 
and fruit fly 238 (mirbase.org, October 2011). Taken together, this point towards the 
fact that miRNAs may work as “fine-tuners” in regulation of gene expression.  
 
There are 1424 miRNA genes in the human genome (mirbase.org), and together they 
may target up to 60% of all protein-coding genes (91). A miRNA usually has a 
relatively mild effect on expression of the target gene. However, each miRNA can 
target several different genes and many of these targets are often in the same pathway 
(133), thus the total impact of miRNAs on the transcriptome and proteome is 
significant.  
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miRNAs can, through their regulation of target mRNAs, be involved in the regulation 
of many biological processes, e.g. cell differentiation, fat metabolism, apoptosis, stress 
and cell proliferation (10, 25, 36). Mice with a non-functional miRNA machinery die 
early with severe developmental defects (30), while knock-out of a specific miRNA 
only has mild effects. Thus, a functional miRNA machinery is critical in normal 
biological processes. Consequently, deregulated miRNA expression may lead to several 
diseases. Altered miRNA levels have been detected in several different cancers, 
infection, cardiovascular disorders, diabetes, inflammation and autoimmunity (58, 67, 
103, 107, 250).  
 
 
1.3.2 miRNA biogenesis 
miRNA genes are transcribed from the DNA by RNA polymerase II into primary 
miRNAs (pri-miRNAs). A pri-miRNA can be several hundreds of nucleotides in length 
and may contain several imperfect hairpin loops corresponding to several precursor 
miRNAs (pre-miRNA). The nuclear protein DGCR8 and the enzyme Drosha introduce 
a cleavage to liberate the hairpin loop from the pri-miRNA. The resulting hairpin, pre-
miRNA, is about 70 nucleotides in length and is exported from the nucleus to the 
cytoplasm. The protein Dicer then cleaves the loop, leaving a double stranded 
miRNA/miRNA* duplex. One strand of the duplex (passenger or miRNA*) is usually 
released and degraded while the other strand, the mature miRNA, is incorporated into 
the Argonaute containing miRNA-induced silencing complex (miRISC), which 
facilitates the interaction between the mature miRNA and its mRNA target (115). The 
biogenesis of miRNAs is illustrated in Figure 4. 
 
 
1.3.3 The role of ER in miRNA regulation 
ER-induced gene regulation involves transcription by RNA polymerase II. Breast 
cancer patients expressing ERα have been reported to express a distinct miRNA pattern 
compared to ERα negative patients (129, 154, 176, 263). Deregulated miRNA has also 
been found in colon cancer (178, 184, 257). Both breast and colon cancers have been 
associated with deregulation of ERα/ERβ. Taken together, this suggests that the ERs 
may exert some of their transcriptional effects via regulation of miRNAs.  
 
Most studies have focused on the effect of miRNAs on ERα  protein or mRNA levels, 
such as miR-221/222, miR-206, miR-27a, miR-22 and miR145 (5, 158, 195, 228, 263) 
and the repressive effect of miR-92 on ERβ (7). However, the regulatory effect of ERα 
and ERβ on miRNAs has not thoroughly been examined. So far, there are no studies 
looking into ERβ-driven regulation of miRNAs, and the published studies on ERα 
regulated miRNAs are somewhat contradictory (31, 248). miRNA-induced 
downregulation of ERα makes MCF-7 and T47D breast cancer cells more resistant to 
tamoxifen induced apoptosis (263). This suggests that these miRNAs might be 
potential targets for improved antiestrogen therapy in breast cancer. It is essential to 
further explore ER regulation of miRNAs since identification of ER regulated miRNAs 
might reveal new biomarkers for diagnosis, success of treatment as well as potential 
targets for novel therapeutics in several different estrogen responsive cancers.  
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Figure 4. The biogenesis of miRNAs. miRNAs are first transcribed into pri-miRNAs in the nucleus by 
RNA polymerase II. Drosha cleaves off an imperfect hairpin loop, the pre-miRNA, which then is 
exported to the cytoplasm where Dicer cleaves off the loop leaving a miRNA/miRNA* duplex. The 
duplex is separated into single strands and the miRNA associates with the RISC complex and is 
transported to its target gene resulting in translational repression or degradation. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Genetics (He L, Hannon GJ. MicroRNAs: small RNAs 
with a big role in gene regulation), copyright (2004) (115).  
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1.4 BREAST CANCER 
Cancer is a major health problem in the western world, and trends show that the rest of 
the world is following in this direction. Breast cancer is the most commonly diagnosed 
form of cancer in women, and is accountable for 29% of all diagnosed cancer cases (1, 
220). Between 15 and 20 women in Sweden are diagnosed with breast cancer every 
day. This form of cancer is much less common amongst men, and approximately 40 
men are diagnosed yearly in Sweden (3).  
 
Most forms of breast cancer are believed to emerge from mutations accumulating 
during the lifetime. The female sex hormones are involved; use of contraceptives 
increases the risk for development of breast cancer while pregnancy at young age 
decreases the risk. 5-10% of all breast cancers are hereditary. Genes that most often are 
mutated are BRCA1 and BRCA2. Women with one or both of these mutations not only 
have higher risk of developing both breast and ovarian cancer, but also tend to be 
affected at an earlier age (13, 177).   
 
In Sweden the incidence of breast cancer has increased with a yearly average of 1.2% 
during the last two decades (1). The reasons behind this are unclear, but two major 
contributing factors are the aging population and introduction of mammography 
screening programs. Screening programs lead to an earlier detection of cancer, and 
might detect tumors in elderly women that previously would die of other causes before 
the cancer was progressed enough to be detected. In addition, a change of dietary 
intake, environmental factors, delay of child birth and the use of hormone replacement 
therapy (HRT) may also contribute to this increase.   
 
The incidence of breast cancer varies widely between more developed regions such as 
western/northern/southern Europe, Australia and northern America and less developed 
regions such as central America, middle/eastern Africa and Asia (81). The incidence 
per 100,000 women is 19.3 in Eastern Africa and 89.7 in Western Europe. Even though 
incidence of breast cancer among Japanese women has increased over the past decades, 
Japan is still considered to be a low-risk country. It has been suggested that the high 
dietary intake of soy foods significantly has contributed to the low incidence of breast 
cancer in Asian countries. Soy foods are rich in isoflavones; plant-derived non-steroidal 
compounds (phytoestrogens) that have estrogen-like properties (6).     
 
 
1.4.1 Breast cancer and estrogen 
There are two major epithelial cell lineages in the mammary gland; luminal and 
myoepithelial. The latter is adjacent to the basal membrane. The major parts of 
mammary gland development take place during three distinct phases; puberty, 
pregnancy and lactation, and is under control of growth factors and the steroid 
hormones estrogen and progesterone (120, 210). A mammary stem cell can self-renew 
and differentiate into all cell types constituting the mammary gland. Estrogen and 
progesterone have been shown to regulate mammary stem cells both in number and in 
ability to propagate into all cell types constituting the mammary gland, despite the lack 
of expressed ER and PR (18, 135). This indicates that steroid over-stimulation of 
mammary stem cells increases the risk for breast cancer development. ERα is critical 
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for regulation of the breast epithelial cell differentiation and proliferation. Females with 
aromatase deficiency will not develop breasts at puberty unless given estrogen 
replacement therapy (134). Studies on ERα knock-out mice have shown that ERα is 
important for normal mammary gland development and is required for development of 
a normal ductal structure (34, 53, 80). ERβ knockout mice showed that ERβ is involved 
in terminal differentiation of the mammary gland but is not involved in ductal growth 
(86). During menstrual cycle, the epithelial ducts and branches will increase, and 
during pregnancy and lactation they will differentiate into milk secreting alveoli cells 
(120, 121). The main ER contributor to the first part is ERα, while ERβ has a 
prominent role in the second one.  
 
ERβ is the predominant ER in the human breast. ERα is only expressed in 10-20% of 
normal resting mammary gland cells (202). In addition to differences in protein 
expression levels, the distribution of the two receptors differs; in rodent, ERβ is found 
in both epithelial and stromal cells while ERα only is expressed in epithelial cells (48). 
The ratio between ERα and ERβ is changed in breast cancer, 70% of all new breast 
cancers express ERα, whereas ERβ is decreased in advanced stages of breast cancer 
(76, 114, 194, 197).  
 
Since estrogen plays such an important role in the mammary gland development, it is 
not surprising that estrogen signaling has a prominent role in breast cancer. 
Upregulation of ERα results in increased proliferation and subsequent progression of 
breast cancer. Estrogen treatment of ERα positive breast cancer cells stimulates 
proliferation while ERβ has been shown to suppress ERα transcriptional regulation 
(105, 113, 183, 230). ERβ levels are decreased or lost in breast cancer progression, 
which may result in a limited inhibitory effect of ERβ on ERα-driven proliferation, thus 
contributing to the pathogenesis of breast cancer. 
 
Most breast cancers, especially in an early stage, are estrogen dependent. This has lead 
to the development of many new therapies targeting the estrogen signaling pathway. It 
has been stated that breast cancer tumors expressing both ERα and the estrogen 
regulated progesterone receptor (PR) will benefit the most from endocrine therapy (16, 
22, 54). In general, tumors expressing ERα have a better prognosis than ERα negative 
tumors and are associated with lower-grade tumors, longer disease-free survival and a 
better overall survival. ERα negative tumors on the other hand have a higher risk for 
metastases and recurrence (22, 51, 143, 202, 247). It is not entirely clear what role ERβ 
plays in breast cancer. However, ERβ KO mice and in vitro studies show a connection 
between decreased or lost levels of ERβ  and a more invasive phenotype, tamoxifen 
resistance and overall poor survival (87, 146). However, ERβ expression seems to have 
multiple effects depending on ERα status and invasiveness of the tumor. ERβ reduces 
proliferation in ERα positive cells, yet reintroduction of ERβ in more invasive ERα 
negative breast cancers has the opposite effect and increases cell proliferation (123, 
234). 
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1.4.2 Treatment of breast cancer 
Even though the incidence for breast cancer has increased during the last decades, the 
chance to be cured from this form of cancer has conversely increased. Detection at an 
earlier stage is one major contributing factor, and also a better understanding of the 
molecular mechanisms behind breast cancer has lead to improved treatments. Breast 
cancer tumors can be divided into different molecular classes depending on the 
expression status of ERα, PR and HER2. Tumors status is determined by molecular 
profiling and therapeutic strategy is then determined based on the molecular class of the 
tumor.  The HER2 protein is amplified in 25-30% of all human primary breast cancers 
(225), and promotes growth and invasion. VEGF is a protein important to tumors by 
stimulating formation of new blood vessels. New treatments for breast cancer 
comprises monoclonal antibodies targeting HER2 and VEGF (e.g. trastuzumab and 
bevacizumab), and can, at least short term, prevent tumor growth and blood supply to 
the tumor. In addition, since most breast cancers express ERα, therapies targeting 
estrogen signaling is widely used in the treatment of breast cancers (tamoxifen, 
raloxifene and aromatase inhibitors) (114). About 15-20% of all breast cancers have a 
triple negative profile (ERα, PR and HER2 negative) (59) and these patients have 
poorer survival compared to hormone responsive subtypes.  
 
 
1.4.3 Endocrine therapies 
Almost 70% of all early breast cancer tumors express ERα, and breast cancer therapies 
targeting this protein have been widely used for decades (202). Early treatment of 
estrogen responsive breast cancer included surgery, but in early 1970‟s a new 
therapeutic approach was started through to the introduction of the SERM tamoxifen 
(187). Five years of adjuvant tamoxifen treatment significantly reduces mortality and 
recurrence for the first 15 and 10 years, respectively (63). Even though tamoxifen gives 
ERα positive breast cancer patients a better overall survival, there still are some 
drawbacks. Endocrine treatment with tamoxifen has been shown to be associated with 
an increased risk of endometrial cancer, blood clots and stroke (83, 84).   
 
ICI 182 780 promotes degradation of the ERα protein and is used as an endocrine 
treatment to ERα positive breast cancer patients who fail to respond to tamoxifen. 
Aromatase is the enzyme responsible for conversion of androgens to estrogen. 
Aromatase inhibitors (AI‟s) such as anastrozole, exemestane and letrozole are widely 
used therapies against estrogen responsive breast cancers. They reduce the primary 
source of estrogen in postmenopausal women, thereby limiting estrogen levels in both 
plasma and tumors. Studies have shown that advanced breast cancer patients favors 
from AI‟s compared to tamoxifen as a first line agent when it comes to overall response 
rate (88, 187, 259). Tamoxifen is today the most widely used initial therapeutic in early 
breast cancer, but combination with AI‟s might improve the overall outcome.  
 
 
1.4.4 Endocrine resistance 
Only approximately 50 to 70 % of all patients with ER-expressing tumors respond 
well to hormonal therapy (164, 189). The majority of all patients that initially respond 
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to tamoxifen develop resistance during treatment (acquired resistance) (128, 211). Also, 
in some tumors tamoxifen might instead stimulate growth of the tumor. ERα-
expressing tumors that are not responding to tamoxifen may be caused by lack of 
and/or modifications in the allele carrying the gene for the enzyme CYP2D6 (239). 
This enzyme is responsible for conversion of inactive tamoxifen to its active 
metabolite; consequently lack of this enzyme will result in lower levels of or no active 
tamoxifen metabolites. Another explanation to endocrine resistance is the presence of a 
tamoxifen resistant clone that during time will take over the tumor cell population (52).  
 
Loss of ERα expression, or mutations of the ERα protein, is one known factor 
contributing to endocrine resistance, although this is only a small fraction of all breast 
cancers (20%) (190). Instead it has been suggested that post-translational modification 
of ERα is responsible for most of the resistance. Phosphorylation of ERα results in 
activation of the receptor independently of estrogen or tamoxifen (41, 181, 223, 244). 
Activation of alternative pathways that can stimulate proliferation and survival are 
involved in endocrine resistance. Resistance can be achieved through crosstalk and 
modulation between these pathways, such as growth factors and kinase pathways that 
phosphorylate ER (17, 174). In addition, these pathways can during endocrine 
treatment develop into drivers of tumor growth independent of ER. Some pathways 
involve HER tyrosine kinase receptor family (e.g. HER2 and EGFR), fibroblast growth 
factor and stress-related kinases (190). HER2 regulates ERα expression and activity 
which in turn stimulates phosphatidylinositol 3-kinase (PI3-K)/Akt signaling (74, 229). 
This ligand-independent activation of ERα results in ERα genomic functions regardless 
of hormone, thus leading to ERα-induced proliferation independent of tamoxifen 
treatment (15, 50, 219). ER+/HER2+ breast cancer tumors might therefore benefit from 
a combined treatment of tamoxifen and inhibitor of EGFR, HER2 and VEGFR (74, 
77). Further, reduced levels of ERβ might be involved in resistance to tamoxifen 
treatment (122, 163). However, other studies suggest that tamoxifen has a negative 
effect in ERβ-expressing breast cancers, by antagonizing ERβ activated growth-
inhibitory genes (157). Therefore, the mechanism behind the potential involvement of 
ERβ in endocrine resistance is not fully understood, and more research is needed.  
 
 
1.5 COLON CANCER 
Colorectal cancer (CRC) is the third most common form of cancer amongst both men 
and women. Colon cancer corresponds to almost 7% of all Swedish cancer cases 
reported to the cancer registry in 2009 (1). Equivalent number for men and women in 
the world is 10% and 9.4%, respectively (81). CRC is a disease more common in 
developed regions, covering almost 60% of all CRC cases in the world (81). Each 
year about 608,000 persons die from colon cancer worldwide, accounting for 8% of 
all cancer deaths. This numbers makes it the fourth most common cause of death 
from cancer. Just as breast cancer, colon cancer incidences in Sweden have been 
steadily increasing during the last decade with an average yearly increase of 1.7 % for 
women and 1.2% for men (1). Each year, about 2,000 men and 2,000 women are 
diagnosed with colon cancer in Sweden.  Also, if rectum and anus cancer were 
included the number would increase to 3,200 and 2,900, respectively (1). Risk factors 
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for developing colorectal cancer include smoking, diet, age, alcohol intake, sex, 
genetic background and intake of hormonal replacement treatment.  
 
 
1.5.1 Cause of colorectal cancer 
Colorectal cancer is caused by uncontrolled growth of the epithelial cells lining the 
colon. It starts as transformation from normal colonic epithelia into benign 
adenomatous polyps which may develop into an advanced adenoma and eventually into 
invasive cancer (170). Development of sporadic CRC is a long multistep process 
involving several different mutations and requires years before it fully develops into 
cancer. Mutations include different tumor suppressors and oncogenes, and one of the 
earliest events in colorectal carcinoma is the inactivating mutation of both alleles of the 
adenomatous polyposis coli (APC) gene. The APC protein is found mutated in 50% 
and 80% of all colorectal adenomas and carcinomas (142). This mutation can either be 
acquired, or inherited. APC was first described 20 years ago through its association 
with an inherited form of colorectal cancer known as familial adenomatous polyposis 
(FAP) (35, 101, 136). FAP is an inherited syndrome characterized by an early onset of 
multiple adenomatous polyps of the colon, and a high risk of developing colorectal 
carcinoma (96, 136).  
 
 
Figure 5. Development of spontaneous CRC from normal epithelium to metastatic carcinoma is a process 
that takes many years, and requires several steps with gene mutations and/or gene loss. Removal of early 
polyps may prevent the progression to carcinoma. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Cancer (Davies RJ, Miller R, Coleman N, Colorectal cancer screening: prospects for 
molecular stool analysis), copyright (2005) (64). 
 
Most mutations of APC are nonsense mutations resulting in a truncated, non-functional 
APC protein (101). APC is a major binding partner and regulator of β-catenin in the β-
catenin-dependent Wnt signaling pathway (14, 203). Loss of APC will lead to an 
accumulation of the β-catenin protein which in turn will activate genes important in 
stem cell renewal and differentiation. When overexpressed, these genes will contribute 
to cancer development. The impact of accumulating β-catenin, by the non-functional 
APC gene, was further demonstrated in vivo where β-catenin knock-in mice showed 
formation of multiple polyps morphologically similar to those found in Apc-knock-out 
mice (109, 191). Kinzler and Vogelstein suggest that APC acts as a “gatekeeper” of 
colonic epithelial cell proliferation (142). The function of a gatekeeper gene is to keep a 
constant cell number in renewing cell populations. A mutation in such gene will result 
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in imbalance between cell division and cell growth. Some colorectal cancers have 
instead a mutated β-catenin pathway leading to its overexpression due to blocked 
degradation or mutations in genes responsible for β-catenin regulation such as AXIN1, 
AXIN2, TCF7L2 or NKD1 (57, 217).  
 
Activating mutations of KRAS and BRAF are other steps involved in transformation 
and progression of CRC. Both these mutations will lead to constitutive activation of 
the RAS/MAPK pathway (28). KRAS is a signal-transduction molecule that 
stimulates cell proliferation, hence an active mutation of this gene will lead to 
uncontrolled cell proliferation (11). Patients with KRAS mutations are more likely to 
overexpress p53 and 95% of these adenomas are classified as advanced (71). 
Mutations of KRAS are not seen in smaller adenomas, and is only seen in 37.7% of  
colorectal carcinomas and advanced adenomas (11).  
 
In CRCs, inactivation mutations of SMAD2 and SMAD4 are found in 5% and 10-
15%, respectively. In addition, it has recently been suggested that inactivation 
mutations can be found in the SMAD3 gene in 5% of CRCs (78).  SMAD2 and 
SMAD3 are important mediators of the TGFβ signalling pathway and form, after 
activation, a complex with SMAD4. The complex translocates to the nucleus where it 
together with coregulators regulates transcription (117).  
 
More mutations besides deregulation of the APC-β-catenin-Wnt signaling pathway, 
KRAS and SMAD2/4 are needed for the cell to transform from an adenoma into an 
invasive carcinoma. One late mutation is in the TP53 gene coding for the tumor 
suppressor p53, which is responsible for monitoring cell division and cell cycle. The 
mutation of p53 results in loss of the wild-type protein, and gain of a missense protein. 
The missense p53 has been suggested to contribute to decreased apoptosis, increased 
tumor angiogenesis and affect tumor cell proliferation (78). p53 mutations are not seen 
in adenomas, but occur in later stages of colorectal carcinogenesis and can be detected 
in 50-70% of all CRC (79). Mutations of other parts of the p53 regulatory pathway, 
such as PUMA, p21 and BAX, may also be involved in the transformation to colorectal 
carcinoma (256). Figure 5 illustrates the progression of normal colonic epithelium to 
metastatic colonic cancer, and the mutations involved.  
 
Most CRC are either inherited (10-30%) or sporadic (65-85%), but some are also 
caused by chronic inflammation (180). Patients with any of the two major forms of 
inflammatory bowel disease (IBD), Crohn‟s disease (CD) and ulcerative colitis (UC), 
have an increased risk of developing colorectal cancer (72, 152). The mechanism 
behind this is not fully understood, but release of several cytokines (IL-6, TNF-α) 
during chronic colitis and low expression of immunosuppressive cytokines (TGF-β and 
IL-10) have been shown to promote tumor growth (27, 29, 149, 204, 212, 231).  
 
 
1.5.2 The role of estrogen in colon cancer 
Low intake in fruit and vegetables and a high intake in red and processed meat have 
been associated with elevated risks of developing CRC (55, 241). However, the impact 
of diet on initiation and development of colon cancer is being debated. In the last few 
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years several prospective epidemiological studies have demonstrated that diet might not 
be as important as previously thought (8, 9, 147, 171).  
 
Since diet might not be as strongly associated with CRC, other etiological factors might 
be more important in the initiation and development of CRC. The gender distribution in 
CRC is quite even, although slightly more men than women are diagnosed (81).  
Interestingly, women have a later onset than men; median age for men to develop CRC 
is 63 while it for women is 73 years (37). After menopause a woman‟s body produces 
less of the sex hormones estrogen and progesterone. For most women, this happens 
between the age of 45 to 50 (95). A screening of 52,882 US patients with metastatic 
colorectal cancer (MCRC) from the Surveillance, Epidemiology and End Results 
registry revealed that younger women (18-44 years old) with MCRC had a better 
overall survival compared to men of the same age. This was however reversed at older 
age (>55 years old) where females diagnosed with MCRC lived shorter than men of the 
same age (119).  These results supported previously published data from a study with 
2,050 CRC patients that demonstrated an opposing effect of gender on the overall 
survival at either side of the age of 50 years (145).  
 
Several studies have shown an association between postmenopausal hormone 
replacement therapy (HRT) and a reduced incidence of CRC (102, 130, 165, 182). The 
Women´s Health Initiative trial was a large randomized trial designed to study the 
effect of hormone replacement therapy with estrogen and progestin in postmenopausal 
women (2). Although the trial was terminated due to an increased risk of developing 
breast cancer for the group receiving the HTR compared to the placebo group, a 
reduced risk for colon cancer amongst the group receiving the HTR was shown (49). 
There has also been several reports on an inverse association between oral 
contraceptives and CRC (161). This indicates that hormonal status seems to play an 
important role in the development of colorectal cancer. This has been supported in 
several in vivo and in vitro studies with estrogen or phytoestrogens: Distribution of 
estrogen to ovariectomized rats reduced the number of chemically induced tumors in 
the colon (227). Phytoestrogens are weak ligands to the ER with chemopreventive 
properties against estrogen related cancers such as breast cancer and colon cancer (150, 
179, 235). Treatment with a dietary fiber that by colonic bacterial enzymes is converted 
to a phytoestrogen, counteracted the intestinal tumorigenesis in ApcMin/+ mice (24) 
and treatment with phytoestrogen from soy resulted in suppressed colon tumor growth 
in male rats (207). Further, one small pilot study with five FAP patients receiving a 
combination of the phytoestrogens curcumin and quercentin showed reduced size and 
number of adenomas after treatment (56). All this support that estrogen has a protective 
role in the development of CRC. 
 
In the normal colonic epithelia, ERβ is the most common form of the two estrogen 
receptors (40, 82, 139, 226, 255). ERβ expression decreases in the progression of 
normal colonic tissue to colon cancer. This decrease of ERβ expression directly 
correlates to apoptosis, correlates to the differentiation grade of the tumor and inversely 
correlates with cell proliferation (23, 85, 131, 144, 185). This suggests that ERβ is the 
mediator of the protective effect of estrogen in CRC. This has further been supported in 
in vitro and in vivo studies: ERβ overexpression in HCT8 colon cancer cells lead to 
decreased cell proliferation (172). Treatment with an ERβ specific agonist, 
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diarylpropionitrile (DPN), in mice that spontaneously develop intestinal adenomas 
(ApcMin/+) resulted in reduced intestinal tumorigenesis (93), and deletion of ERβ in 
these mice had the opposite effect increasing both number and size of adenomas (94). It 
has also been demonstrated that estrogen stimulated ERβ reduced cell growth in 
nontransformed colonocytes, implying a role for ERβ in the protection of the 
colonocytes from malignant transformation (243). All together, this supports the role of 
ERβ in colon cancer; both as a protector against CRC initiation as well as inducer of 
decreased proliferation in already transformed colon cancer cells. However, the 
mechanisms behind this are still rather unexplored. To further establish ERβ‟s role as a 
target for CRC prevention or therapy, more studies are needed, both in vitro, in vivo 
and in the clinic using ERβ specific ligands. In addition, a better understanding of gene 
pathways activated by ERβ will help to further dissect the impact of ERβ in CRC and 
might serve as a tool to improve diagnostics, adapt and select proper therapeutic 
treatments and help to predict clinical outcome of CRC patients. 
 
 
1.6 GENOME-WIDE TECHNIQUES TO STUDY GENE EXPRESSION 
The focus in this thesis has been to explore genome-wide effects of the estrogen 
receptors. There are several different techniques that can be applied and below are short 
explanations of a few of them. 
 
 
1.6.1 Microarray 
The microarray technology has been widely used in genome-wide gene expression 
studies since the late 1990s (215, 216). This technique offers an easy and rather cheap 
method to study differences in gene expression between samples. The basics behind 
microarrays are deposition of DNA corresponding to the full transcriptome, where each 
gene is represented by one or several probes, on an array. A sample cDNA, labeled 
with fluorescent dyes, is hybridized onto the probes. The fluorescent intensity of each 
probe corresponds to the abundance of that gene transcript in the sample. Independent 
of platform used, microarray data needs to be confirmed with other techniques such as 
real-time PCR. This is especially true for low abundant genes.   
 
Several different companies offer varying techniques and manufacturing of 
microarrays. Affymetrix is one of the most commonly used microarray platforms (73).  
Probes on the GeneChip from Affymetrix contain 25-mer oligonucleotides, synthesized 
directly on the microarray surface, where the probe sequence is built one base per 
cycle. Each gene is represented by several different oligonucleotides known as a probe 
set, both perfectly matched to the target transcript as well as mismatched sequences 
(73). Specific binding is determined through the signal difference between matched and 
mismatched transcripts in a probe set. One sample is hybridized per array, meaning that 
a comparison between two samples requires two arrays. While Affymetrix uses 
photochemical synthesis to print arrays with short oligonucleotides, Agilent offers 
printed arrays with 60-mere oligonucleotides using InkJet technology. In addition to 
offering single-color arrays, Agilent also provides dual-color arrays where the two 
samples to be compared are hybridized on the same array slide. Another technique is 
the spotted array where (25-70 mere) pre-synthesized oligonucleotide probes are 
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attached onto the glass array. These probes can be produced “in-house” of academic 
laboratories or companies, or can be bought as ready-made collections of 
oligonucleotides (e.g. Operon‟s 35k 70mer library covering all known human genes). 
Spotted arrays are usually two-channeled which means that each of the two samples are 
labeled with different fluorescent dyes and hybridized onto the same array. A different 
technique is offered by Illumina, where the oligonucleotides are attached to small beads 
instead of a glass slide. One benefit of Illumina is the possibility to process several 
samples in parallel.  
 
The major benefit of printed arrays is the possibility to add more probes onto an array 
that what mechanically is possible for spotted arrays. Spotted arrays have the capacity 
to cover all know genes. However, the benefit with more probes, as offered by printed 
arrays, is the possibility to add replicates as well as splice variants. Both Affymetrix 
and Illumina offer multiple replicates for each gene, thereby increasing the possibility 
to detect differentiated genes despite of one bad probe. The drawback of Illumina 
compared to Affymetrix is that each transcript is detected with multiple probes with the 
same sequence instead of multiple probes with different sequences (73). Benefits of 
spotted arrays are the cheaper price and the possibility to customize the array for each 
experiment. However, results from custom made spotted arrays may not be so easily 
compared to results from commercially printed arrays due to reduced sensitivity, 
reduced printing efficiencies and reduced quality with missing spots (21, 73). 
Commercially available printed arrays have been quite expensive, but during the last 
years, both Affymetrix and Agilent arrays have drastically dropped in price. Still, 
purchasing spotted arrays are considerably cheaper.  
 
microRNA microarrays are commonly used in large-scale miRNA studies and several 
companies offer commercial arrays for miRNA expression analysis. miRNA arrays are 
rather new in the field of microarrays, and it has not been thoroughly established how 
to analyze the data. Because of the small size of the miRNome compared to the 
genome, one challenge is the normalization of miRNA microarray data (125, 206). 
Therefore, it is essential to validate miRNA microarray data with other techniques 
available. 
 
 
1.6.2 Real-time PCR 
Real-time PCR (quantitative real-time PCR/qPCR) is the most sensitive method to 
study the relative level of a specific RNA between two samples. Total RNA extracted 
from cells or tissues of interest is reversely transcribed to cDNA and then amplified 
using forward and reverse primers and analyzed in real-time. The data is measured and 
presented while the run is ongoing, thus the name „real-time‟. 
  
There are several different chemistries available for real-time PCR, the two most 
common being TaqMan and SYBR green. Both these chemistries generate fluorescence 
which will be relative to the amount of PCR product produced. TaqMan utilizes a 
sequence specific probe as well as primers specific for the gene of interest. The probe is 
an oligonucleotide containing a 5' fluorescent dye and a 3' quenching dye, designed to 
hybridize to an internal region of a PCR product. As long as the dyes are in close 
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proximity there will be no fluorescence. As the PCR product extends to the probe, it 
will be cleaved off by Taq polymerase and the dyes will separate resulting in 
fluorescence (127). SYBR green, on the other hand, binds to all double stranded DNA 
and will give a stronger signal as more DNA is amplified for each cycle of the PCR 
run. SYBR green primers therefore need to be carefully designed for optimal 
selectivity, and checked with melt curve analysis to ensure a pure PCR product, not 
containing unspecific fragments or primer dimerization. The advantages and 
disadvantages of the two techniques are that TaqMan is more specific but more 
expensive, while SYBR green is more cost effective but requires additional controls to 
ensure gene specificity.   
  
Advantages of real-time PCR compared to microarrays are the sensitivity, specificity, 
and simplicity. However, some important considerations for real-time PCR are the need 
for a good reference gene and well designed, gene specific primers. This, together with 
the higher cost for primers and reagents for a large number of genes, limits the use of 
this method to studies exploring changes in a small set of genes such as confirmation of 
microarray data, rather than for a screening study of genome-wide changes. However, 
this limitation has somewhat been bypassed through the development of large scale 
real-time PCR plates. Real-time PCR plates already containing optimized gene specific 
primers covering either parts of the genome, a specific pathway or genes involved in a 
specific disease, are commercially available. The TaqMan low density arrays (TLDA) 
microRNA cards from Applied biosystems, covering most known miRNAs, are an 
example of large-scale analysis of the miRNome. One limitation with large-scale real-
time PCR analysis is the decreased accuracy and specificity for low copy number 
genes, resulting in higher ΔCt variances between intra-plate assays compared to high 
copy number genes (166). 
 
 
1.6.3 RNA sequencing 
Both microarrays and real-time PCR are widely used in analyses of gene expression 
due to their simplicity and low price. However, a growing field for genome-wide 
analyses is RNA sequencing (RNAseq). RNAseq has both advantages and 
disadvantages where one of the biggest advantages is that while microarrays only can 
detect transcripts present on the array, RNAseq can detect known and unknown genes 
as well as different splice variants and mutations (168). However, the cost for RNAseq 
is much higher than a microarray experiment, and might lead to a reduction of 
biological replicates being analyzed. In addition, since microarrays have been around 
for almost two decades, strategies for analyzing the data with minimal biases have been 
optimized, while it for RNAseq still is under development. Another major drawback is 
the magnitude of data generated from an RNAseq run. RNAseq data analysis requires 
knowledge in bioinformatics and data programming. It will take some time to develop 
tools for easy analysis of the data, but the more research that is done with this 
technique, the simpler and cheaper it will be (168). Despite the present drawbacks for 
RNAseq, this is a growing field that will become more common in the future. 
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2 AIMS OF THESIS 
The general aim of this thesis was to increase the overall knowledge about the functions 
of ER and ER by studying their effects on gene transcription, with focus on their 
implications in breast- and colon cancer cells. Specifically, our objectives were: 
 
I. To investigate the differences and similarities in transcriptional regulation 
by the two estrogen receptors in T47D breast cancer cells (Paper I). 
 
II. To dissect the ER-driven regulatory networks, through analyzing 
miRNA expression following estrogen stimulation of ER in T47D breast 
cancer cells (Paper II). 
 
III. To study the role of re-introduction of ER in the human colon cancer cell 
line SW480, with focus on cell cycle regulation and impact in xenograft 
tumors (Paper III). 
 
IV. To gain a better understanding of ER transcriptional regulation in three 
colon cancer cell lines through transcriptome analyses and bioinformatics 
(Paper IV). 
 
V. To explore ER-driven changes of the miRNA pool and correlating 
mRNA regulations in SW80 colon cancer cells (Paper V).  
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3 METHODOLOGICAL CONSIDERATIONS 
 
In any experimental system, significant considerations need to be taken into account 
when deciding on the methodological layout as well as for data interpretation. 
Considerations and limitations of some of the major methods and systems used in the 
studies in this thesis are described below. Other considerations are discussed 
throughout each study. 
 
 
3.1 CELL LINES 
The cell lines used in this thesis were immortalized from different breast and colon 
cancer tumors, and purchased from American Type Culture Collection (ATCC). Cell 
lines are a useful tool for in vitro models in cancer research since they are easy to grow 
and can be cultured infinitely. However, due to their continuous culturing they are 
prone to undergo genotypic changes thereby creating different subpopulations. Two 
different labs working with the same cell line might get different results depending on 
culture conditions and passage number of the cells.  
 
In addition, cancer is a complex disease with diverse genetic backgrounds and many 
separate, activated signaling pathways leads to the progression of the disease. 
Therefore, an immortalized cell line cannot be seen as the perfect model system for that 
particular type of cancer. An alternative approach is to generate primary cultures 
directly from tumors. However, since primary cultures grow slowly and have a definite 
lifespan of just a few passages, the use of primary cultures is limiting when large 
amounts of cells are needed.  
  
Since ERβ expression decreases during breast and colon cancer progression, no cancer 
cell line exist that express significant amounts of endogenous ERβ. The lack of 
immortalized cell lines expressing ERβ is one of the challenges when studying its 
transcriptional regulation. We therefore used systems where we introduced ERβ into 
the cells, thereby restoring the lost endogenous expression of ERβ. These methods will 
most likely not fully restore the physiological situation of the lost ERβ, but serves as an 
excellent tool for in vitro mechanistic studies and as guidance for future in vivo studies. 
 
The two breast cancer cell lines used, MCF-7 and T47D, both express significant levels 
of endogenous ERα, and in our study express ERβ under the control of an inducible tet-
off system. The three colon cancer cell lines used, SW480, HT29 and HCT-116 have 
low or no expression of endogenous ERα or ERβ, and were made to express ERβ 
through lentiviral transduction. 
 
 
3.2 BIOINFORMATICS 
Bioinformatics is a powerful in silico tool to analyze vast amounts of data. In this 
thesis, bioinformatics have been employed for microarray analyses, for gene ontology 
overrepresentation analyses, for genome-wide comparisons of ChIP with our 
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microarray data, for identifying predicted miRNA mRNA targets, for incorporation of 
literature searches and for building regulatory networks and pathways. However, as 
with any other method there are some limitations to take into consideration. There are 
many databases freely available with large amounts of data from different in vivo and in 
vitro experiments. However, tissue and cell specific effects are often not accounted for, 
and data that is true in one cell line might not be true in another cell line, even if they 
both come from the same type of cancer. In addition, chromatin binding site studies for 
a particular transcription factor might be similar in different cell lines, but will differ 
depending on presence of e.g. cofactors and packing of the chromatin. miRNA target 
predictions are algorithms calculating the most statistical probable target. All the 
different miRNA target predicting sites have different algorithms, thereby resulting in 
different responses despite the same in-data. 
 
Bioinformatics can be used to find new angels and insights on obtained in vitro/in vivo 
results, and build new experiments based on that.  
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4 RESULTS AND DISCUSSION 
 
 
4.1 PAPER I: A GENOME-WIDE STUDY OF THE REPRESSIVE EFFECTS 
OF ESTROGEN RECEPTOR BETA ON ESTROGEN RECEPTOR 
ALPHA SIGNALING IN BREAST CANCER CELLS 
ERα mediates a proliferative effect in estrogen responsive breast cancers, and therapies 
targeting ERα are used in the clinic. It has been suggested and demonstrated in vitro 
that that ERβ opposes this effect of ERα. Most patients that initially respond to ERα 
targeting therapies develop resistance over time. New therapies are needed, and ERβ is 
a potential target. However, the clinical significance of ERβ in diagnostics and 
treatment has not been established. Thus, there is a need for a better understanding on 
the underlying mechanism of the supposedly antiproliferative effect of ERβ. In Paper I, 
we performed a genome-wide analysis of ERα and ERα/ERβ transcriptional activity, 
with the aim to elucidate the different regulatory networks of the two receptors (251). 
 
We used T47D cells and expressed ERβ through a tet-off system. ERβ was expressed 
for 24 hours prior 24 hours treatment of ICI or E2 in control cells and ERβ-expressing 
cells. Changes in gene expression were studied using microarray and real-time PCR. 
Our analysis identified 1434 ERα regulated transcripts, out of which 998 genes were 
inhibited by ERβ expression. In addition, we found a large proportion of genes 
regulated by ERα alone or by ERβ. 80% of the 50 strongest ERα regulated genes were 
induced by E2, while the corresponding number for ERβ was 26%. This illustrates that 
ERα predominantly had an upregulatory effect while ERβ negatively modulated a 
majority of its targets. This pattern was also seen in the genes commonly regulated by 
the two ERs, where 76% were upregulated by ERα and attenuated by ERβ. In addition 
to genes regulated both by ERα and ERβ, we also detected altered expression of genes 
in ERβ-expressing cells that were not affected by ERα, revealing an ERβ specific 
regulation. After removing boarder-line ERα regulated transcript, we had a list with 49 
transcripts regulated by ERβ alone, out of which 71% were upregulated.  
 
Gene ontology analysis of all ERα regulated genes showed that the most 
overrepresented category for downregulated genes was related to the „cell cycle‟, and 
for upregulated genes to „cell adhesion‟, „oncogenesis‟ and „apoptosis‟. A 
corresponding analysis for all ERβ regulated genes showed an enrichment of 
downregulated genes within „cell proliferation‟ and an enrichment of upregulated genes 
within „negative regulation of cell growth‟ and „apoptosis‟. Further, a parallel analysis 
of genes regulated both by ERα and ERβ showed an enrichment of genes within the 
„cell cycle‟. The fact that gene ontology analyses for both ERs showed an enrichment 
of genes within categories such as cell cycle and cell growth, further supported ERα‟s 
proliferative effect and ERβ‟s antiproliferative effect. In addition, we could confirm this 
antiproliferative effect with a proliferation assay in which the estrogen stimulated ERα-
induced proliferation in T47D cells was completely abolished when ERβ was 
expressed.  
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Many of the ERα-regulated genes opposed by ERβ, such as several cyclins (CCNA2, 
CCNB1, CCNB2, CCND1 and CNF), pS2, BCL2, GREB1, MYC and TP53INP1, are 
involved in proliferation and cell-cycle regulation. In addition, ERβ alone regulated 
several antiproliferative genes, such as QSCN6, NDRG3, SEPT9, KCTD11 and STK3. 
IL-20 was one of the most strongly induced ERα-regulated genes that was opposed by 
ERβ. IL-20 stimulates epithelial cell proliferation, antiapoptotic response, can enhance 
wound-healing activities and is involved in skin inflammations (192, 209). Deregulated 
IL-20 expression may lead to uncontrolled tissue repair processes resulting in diseases 
(192). Thus, the opposing effect by ERβ on the proinflammatory cytokine IL-20 as well 
as the regulation of several genes involved in proliferation and cell-cycle regulation 
may therefore contribute to the antiproliferative properties of ERβ.  
 
In an effort to elucidate the mechanism behind ERβ‟s opposing effect on ERα 
signaling, we transfected T47D cells with an ERβ protein with a mutated DNA-binding 
domain. We saw that the opposing action of ERβ on some of the ERα regulated genes 
was in fact accentuated when ERβ had a mutated DNA binding domain and was unable 
to bind to the DNA. One possibility is that ERβ heterodimerizes with ERα resulting in 
reduced binding efficiency to the ERE compared to an ERα homodimer, thus 
explaining ERβ‟s opposing effect and lack of full inhibition of the ERα-driven 
transcription. However, when the mutated ERβ heterodimerizes with ERα, the ability to 
bind to ERE is fully abolished.     
 
Comparison of our T47D microarray data with previously published studies on ERα 
transcriptional regulation in MCF7 cells showed many common regulations (89). These 
were found despite the use of different cell lines, different treatments (ICI or vehicle) 
and different technology platforms. In addition to already published data, this study 
also contributed with a large number of novel ERα regulated genes, possibly cell 
specific. Few studies of ERβ transcriptional regulation had been published at the time. 
Comparison with the one published study in, MCF7 breast cancer cells, found many 
discrepancies (45). This may be contributed to different cell lines, different mode of 
ERβ delivery (tet-off construct versus transient adenoviral gene delivery) and the use of 
different microarray platforms. Nonetheless, both studies could show the same gene 
groups, such as cell-proliferation and ion homeostasis, being affected by introduction of 
ERβ in ERα-expressing cells. 
 
In conclusion, we could show that ERβ opposed the effect of ERα-driven upregulation 
of genes involved in cell proliferation and cell cycle in T47D breast cancer cells, which 
we also functionally confirmed with a proliferation assay. Further, we demonstrated 
that ERβ not only opposes ERα transcription, but also induced transcriptional changes 
independently of ERα.  
 
  
4.2 PAPER II: ESTRADIOL-ACTIVATED ESTROGEN RECEPTOR α DOES 
NOT REGULATE MATURE MICRORNAS IN T47D BREAST CANCER 
CELLS 
microRNAs (miRNAs) have been shown to be involved in several different cellular 
processes and is often deregulated in cancers, including breast cancer. Both mRNA and 
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miRNA are transcribed from the DNA by RNA polymerase II. Since estrogen can give 
rise to transcriptional regulation of protein coding genes in breast cancer (by RNA 
polymerase II), it is possible that miRNAs are transcribed by the same mechanism. 
Identification of miRNAs associated with disrupted estrogen signaling could therefore 
contribute to an enhanced understanding of the molecular processes underlying 
development of estrogen related breast cancer. Some studies have investigated ERα 
regulation of miRNAs in MCF7 breast cancer cells, but have presented conflicting 
results. In Paper II, we performed a thorough analysis of miRNAs regulated following 
24 hours estrogen stimulation of T47D cells endogenously expressing ERα (137). We 
utilized several different techniques to identify changes in the miRNA pool. For the full 
miRNome analysis, we used both dual-color microarrays and TaqMan Low Density 
Arrays. Real-time PCR confirmations were then extensively performed with both 
SYBR Green and TaqMan chemistry. 
 
First, we confirmed that 24 hours estrogen stimulation of T47D cells induced expected 
transcription of protein coding genes. pS2, KCNK5 and SPINK4 have all previously 
been shown to be regulated by ERα (251) and were therefore used as positive controls 
of gene transcription. We could confirm that 24 hours of estrogen treatment of T47D 
gave rise to a strong and significant transcriptional response on these genes. Further, 
treatment with ICI showed a decreased response on these genes. Thus, we could show 
that ERα induced transcription of mRNA in these cells. Our miRNA microarray 
revealed no significantly changed miRNAs after estrogen treatment whereas TLDA 
analysis detected 57 regulated miRNAs. However, these TLDA detected regulations 
could not be confirmed with real-time PCR (neither SYBR Green nor TaqMan).  
 
Since the combined analysis with microarray, TLDA and real-time PCR did not show 
any significantly changed miRNAs, a literature study was performed to identify 
miRNAs previously indicated to be changed by ERα. Real-time PCR could not confirm 
an ERα-driven regulation on these miRNAs in T47D cells. Given that most published 
studies have been performed in MCF-7 cells, we also analyzed these miRNAs with 
real-time PCR in these cells. Despite the use of identical cell line, we could not show a 
direct regulation by ERα on these miRNAs. To further explore if estrogen exposure 
time would affect miRNA regulations, we performed times series with estrogen 
treatment in T47D cells. These studies did not show any change on miRNA regulation. 
This conflicts with previously published articles, highlighting the technical challenges 
when it comes to miRNA expression profiling.  
 
In conclusion, even though there was a strongly induced estrogen-activated ERα-
mediated gene transcription at 24 hours in T47D cells, no mature miRNAs were found 
to be significantly regulated.  
 
 
4.3 PAPER III: TUMOR REPRESSIVE FUNCTIONS OF ESTROGEN 
RECEPTOR β IN SW480 COLON CANCER CELLS 
The two estrogen receptors are sometimes co-expressed, often in varying ratios in 
different cell types. The development of estrogen dependent cancer can be facilitated 
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by changes in ratio of the two receptors. Both ERα and ERβ are expressed in the 
normal breast epithelia but as breast cancer progresses, the ratio between them changes, 
often by a decrease of ERβ and an increase of ERα. It is therefore of interest to study 
transcriptional effects by both receptors expressed in breast cancer cells. However, in 
the normal colonic epithelium where levels of ERα are significantly lower or not 
expressed at all, ERβ is the major estrogen receptor, and is often decreased or lost as 
colon cancer progresses. Hormone replacement therapy has been shown to reduce the 
risk for colon cancer, implying a protective role for estrogen in development of colon 
cancer. This point towards a potential tumor suppressor function of ERβ in colon 
cancer. For that reason, it is of interest to study the effect of ERβ alone in colon cancer 
cells. The aim of Paper III was to study the molecular effect of reintroduction of ERβ in 
SW480 colon cancer cells and especially its implication on cell cycle regulations (112). 
 
Following lentiviral transduction with an ERβ-expressing construct in SW480 colon 
cancer cells, proliferation was significantly decreased compared to control cells. FACS 
analysis confirmed this, showing that 75% of the ERβ-expressing cells were halted in 
G1 phase while the equivalent number for the control cells was 52%. Cells transfected 
with an ERβ DBD-mutant did not show this antiproliferative effect, and resulted in a 
nearly complete removal of the ERβ-driven G1 arrest (58%). This demonstrates that the 
ERβ-driven antiproliferative effect in SW480 colon cancer cells was ERE-dependent. 
  
To corroborate the in vitro proliferation results in vivo, we performed a xenograft study 
with SW480 ERβ and control cells in immunodeficient mice. This study showed a 
reduction in tumor weight by 65% in the ERβ-expressing cells. Apoptosis was not 
affected by ERβ, as demonstrated with a TUNEL assay, which made us conclude that a 
changed apoptosis potential was not the cause of the smaller size of the ERβ-expressing 
xenografts. However, ERβ-expressing tumors exhibited a significant reduction of Ki67 
positive cells compared to control xenografts, confirming that ERβ mediated a reduced 
proliferation, resulting in the smaller sized xenograft tumors. 
 
Western blots reviled ligand-independent effects by ERβ. This may be caused by the 
overexpression of ERβ, but alternative causes will be further discussed in a section of 
Paper IV.  
 
Stimulation of cells with growth factors will result in upregulation of cell-cycle and cell 
proliferation genes. One early response gene is MYC, and this gene was strongly 
downregulated by ERβ. MYC has a central role in colon cancer growth (238) where it 
is an activator of many G1-S phase genes. The ERβ-driven downregulation of MYC is 
thus an important event contributing to the antiproliferative function of ERβ in SW480 
cells. Other key regulators of cell cycle are cyclin-dependent kinases (CDKs), where 
CDK2, 4, 5 and 6 are involved in G1 phase progression. Western blot showed that the 
MYC target gene CDC25A was repressed in ERβ-expressing cells. CDC25A activates 
CDK2 and CDK4; thus, low expression of this protein results in high levels of the 
inactive form of CDK2/CDK4 thereby halting the cells in G1 phase. Further, ERβ-
induced downregulation of the p45 protein, a regulator of p27 degradation, resulted in a 
strong induction of the p27 protein. ERβ also upregulated p14ARF, a tumor suppressor 
involved in cell-cycle arrest. p14
ARF
 in turn downregulates MDM2, resulting in a 
stabilization of the p53 protein that, consequently, was strongly induced in ERβ-
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expressing cells. p53 promotes p21 expression, which also was upregulated. The two 
upregulated proteins p27 and p21 function as CDK2 inhibitors. ERβ expression did not 
induce a change on p15 and p16. Cyklin D1 was upregulated by ERβ, while cyclin E 
and A, both important in late phase of G1, were not. Figure 6 illustrates CDKs and 
regulators of cell cycle progression, as well as the effect ERβ expression had on 
respective protein level, indicating that the antiproliferative effect mediated by ERβ is 
primarily through halting the cells in G1 through the changed expresison of several 
CDK regulators. 
 
 
Figure 6. The cyclin-dependent kinases CDK2/4/5/6 are all important in regulation of cell 
cycle and the G1/S progression. Several CDK regulators were changed following ERβ 
expression (genes in red were upregulated, and genes in blue were downregulated), 
suggesting an explanation for the G1 phase arrest and following decrease in proliferation in 
SW480 colon cancer cells.  
 
Taken together, ERβ demonstrated an antiproliferative role in SW480 colon cancer 
cells in vitro as well as in xenografts and affected proliferation partly through 
transcriptional regulation of genes involved in cell cycle regulation such as MYC, 
p14
ARF
, p53, p21, p45, p27 and CDC25A. Further, we saw that ERβ had significant 
ligand-independent effects. 
 
 
4.4 PAPER IV: ESTROGEN RECEPTOR β INDUCES ANTI-
INFLAMMATORY AND ANTITUMORIGENIC NETWORKS IN COLON 
CANCER CELLS 
Introduction of ERβ in both breast and colon cancer cells results in reduced 
proliferation and changes in key cell cycle proteins (112, 230, 251). The genome-wide 
study performed in T47D cells (Paper I) dissected ERβ transcriptional effects in 
combination with endogenously expressed ERα. ERβ genome-wide regulation on its 
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own is, however, not known. To further elucidate the mechanism behind ERβ‟s 
antiproliferative effect in colon cancer cells, and regulation by ERβ homodimers alone, 
we performed a genome-wide analysis on three colon cancer cell lines with induced 
expression of ERβ (Paper IV) (70). 
 
Stable ERβ expression resulted in large genome-wide transcriptional changes in all 
three cell lines. Although the impact of ERβ was significant, few regulated transcripts 
were found in common between the different cell lines. Just like there were differences 
in ERβ regulated genes in our T47D study compared to published ERβ regulation in 
MCF-7 cells, we here demonstrated that ERβ gene regulation is cell specific also in 
different colon cancer cells. In an effort to further understand ERβ regulations, we 
analyzed enriched gene ontology groups in the three cell lines. Even though different 
genes were regulated, the GO analysis showed an enrichment of genes within protein 
binding, apoptosis, regulation of cell cycle, cell differentiation and kinase activity in all 
three cell lines. ERβ therefore seems to regulate similar biological events, but uses 
different genes in the process. Cell specific activity could be caused by already 
activated pathways, mutations, presence of coregulators and cell specific genes in that 
particular cell. Some known differences in these three cell lines are mutations in p53 
and varying levels of RAS, PROX1, MYC and DNA repair genes.   
  
Once established that there were large variations between the different cell lines, we 
focused our studies on SW480 colon cancer cells. Enriched sub-network analysis 
revealed regulation of many downstream targets of IL-6. Real-time PCR could confirm 
a strong ERβ-driven downregulation on IL-6. In addition, we also found reduction of 
mRNA levels of downstream targets (SP-1, VEGF, JUN1) in the MAPK/ERK pathway 
in ERβ-expressing cells in the two other colon cancer cell lines HT29 and HCT-116. 
Previously we have revealed that ERβ opposed the ERα upregulatory effect on IL-20 in 
breast cancer cells, and here we have shown that ERβ downregulates IL-6 and many 
target genes in the MAKP/ERK pathway. This suggests a role for ERβ in inflammation. 
A randomized clinical trial with hormone therapy as treatment for rheumatoid arthritis 
in post-menopausal women showed suppressed signs of inflammation (60), supporting 
the role for estrogen in treatment of inflammation. A key component in inflammatory 
signaling is NFB. The ERs are known to inhibit NFB inflammation response through 
several different pathways such as competing for the transcription coactivator CREB 
binding protein (CBP) (110), prevention of NFB DNA binding (106) or as a positive 
transcriptional cross-talk between NFB and ER (90). Most of these studies have 
however been performed in ERα positive breast cancer cells, and the mechanism 
behind the potential inhibitory role of ERβ on NFB inflammation response in colon 
cells is not well studied. There is a connection between inflammation and 
tumorigenesis, where chronic intestinal inflammation proceeds tumor development. An 
ERβ-mediated regulation of the inflammatory pathways could, in normal colonic 
epithelia in vivo, significantly contribute to the suggested colon cancer protective effect 
of estrogen and should be examined more thorough.   
 
PROX1 is a transcription factor and nuclear receptor coregulator. It is often 
overexpressed in colon adenomas, in which high PROX1 expression is associated with 
poor tumor differentiation (199, 224). We found that re-expression of ERβ in SW480 
colon cancer cells led to a downregulation of PROX1 both at mRNA and protein level. 
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To our knowledge, this is the first time it has been shown that ERβ expression can 
affect PROX1 levels. It is plausible that the ERβ-driven downregulation of PROX1 is 
responsible for some of ERβ‟s antitumorigenic properties. Comparison of ERβ-
regulated genes to a PROX1 silencing microarray study (199) revealed many 
commonly changed genes, suggesting that regulation of these genes was a direct 
consequence of the ERβ-driven downregulation of PROX1. Further, PROX1 chromatin 
binding sites (as published (46)) were enriched in the proximity of ERβ regulated 
genes. Interestingly, several of these transcripts had both a PROX1 and an ERβ binding 
site. With PROX1-ChIP we could confirm CITED2 as a gene regulated by both 
PROX1 and ERβ, with a PROX1 binding site, in SW480 cells, less than 50 kb from 
TSS. It is therefore possible that PROX1 and ERβ compete and/or co-regulate each 
other to influence the regulation of common target genes.  
 
An ideal model to study the role of ERβ in colon cancer would be a colon cancer cell 
line endogenously expressing ERβ. However, to our knowledge no such cell line exists. 
We therefore need to rely on a model system where we express ERβ. The model we 
used, with stable expression of ERβ in mixed cell populations, made it impossible to 
distinguish between directly regulated transcript and secondary events. As a part of the 
analysis we utilized data from an ERβ binding study in MCF-7 cells with the 
assumption that ERβ binding sites in MCF-7 also exist in SW480, and compared it to 
our genome-wide data. Based on the MCF-7 dataset, 11% of the genome had an ERβ 
binding site. We found an enrichment of genes with an ERβ binding site in our ERβ 
regulated genes (17%). The regulated genes that possessed an ERβ binding site are 
potentially directly regulated by ERβ.   
 
Further, no ligand-dependent ERβ regulatory effects were detected. Several studies 
have published ligand-independent gene regulations by both of the ERs. Mechanism 
behind this is not fully understood, but includes phosphorylation of the AF-1 domain 
via the MAPK pathway and ligand-independent association with the steroid receptor 
coactivators SRA, SRC and CBP to the AF-1 domain (65, 236, 237). We suggest that 
the observed ERβ ligand-independent regulation is caused by high MAPK 
phosphorylation activity. A recent study showed that estrogen stimulated ERβ had a 
protective effect in noncancerous colonocytes (243). We hypothesize that ERβ has a 
ligand-dependent protective role in normal colon epithelial cells, but that this ligand-
dependence for some unknown reason is lost upon re-expression in colon cancer cell 
lines.  
 
In conclusion we have shown that reintroduction of ERβ in colon cancer cells resulted 
in large and cell specific transcriptional changes. These regulations reduced 
proliferation and tumorigenic potential and included, for instance, genes in the 
MAPK/ERK signaling pathway. We could also conclude that the colon carcinogenic 
activity of PROX1 in SW480 cells was affected by ERβ in dual ways; through down-
regulation of PROX1 itself, and through co-regulation of the target genes. 
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4.5 PAPER V: ESTROGEN RECEPTOR BETA EXPRESSION INDUCES 
CHANGES IN THE MIRNA POOL IN HUMAN COLON CANCER CELLS 
No studies so far have looked at a possible ERβ regulation of miRNAs. We speculate 
that some of ERβ‟s antiproliferative effect and some of the transcriptional mRNA 
changes we detected after ERβ re-expression may be attributed to miRNA regulations. 
In Paper V, we performed a large-scale miRNA analysis in SW480 colon cancer cells 
that stably expressed ERβ, and correlated the changes to the transcriptome analysis 
previously performed (70). 
 
We could show that ERβ expression induced significant changes in the miRNA pool in 
SW480 cells, and defined 25 downregulated miRNAs and 3 upregulated miRNAs 
using miRNA real-time PCR confirmations. To investigate the impact of the changed 
miRNA pool, we used bioinformatics to identify predicted target genes and related 
these to the regulated mRNAs (70). We found an extensive overlap of predicted 
miRNAs targets and ERβ regulated mRNAs. We believe that this finding can serve as a 
guide for future studies exploring the complexity of ERβ transcriptional regulation.  
  
As a first step to examine direct ERβ regulatory effects on the changed miRNAs, we 
investigated whether or not there were ERβ binding sites nearby the chromosomal 
location of the miRNAs. We found several miRNAs with proximal and distal binding 
sites, and 66% of the pre-miRNAs had an ERβ binding site within 100kb. This 
indicated a possible direct ERβ regulation for many of the regulated miRNAs. Other 
miRNAs may not be primary targets of ERβ, but rather secondary events of ERβ-
regulated transcription factors. MYC is downregulated by ERβ via a chromatin binding 
site less than 70kb from its promoter (100, 262). MYC is a key regulator of miRNAs 
(38, 140, 186) and miR-200a, miR-200b, miR-9-3, miR-106a, miR-221, miR-135a-1 
and the miR-17-92 cluster have all been shown to be regulated by MYC in other cell 
lines. Thus, these twelve miRNAs may be changed as a consequence of the ERβ-driven 
downregulation of MYC in SW480 cells. 
 
miR-200a and miR-200b were strongly downregulated in ERβ-expressing cells. The 
expression of these miRNAs is decreased in some cancers (68). They have both, in 
other cell lines, been shown to target ZEB1 and thereby lead to the upregulation of 
CDH1 (E-cadherin). Thus, the miR-200 family is believed to be involved in tumor 
suppression through the inhibition of the epithelial-mesenchymal transition (EMT) 
therefore inhibit formation of metastases. Using miR-200a and miR-200b mimics, we 
confirmed ZEB1 to be a target gene, resulting in the subsequent upregulation of E-
cadherin. This regulation does not explain the protective role of ERβ, and the impact of 
miR-200 downregulation in colon cancer needs to be further explored. However, it has 
been demonstrated that miR-200 expression also can promote metastatic properties of 
some cancer cells, suggesting that changed expression of the miR-200 family will have 
different impact on disease outcome depending on cellular context (68). 
  
Another interesting finding was the strong downregulation of the miR-17-92 cluster, 
also known as Oncomir-1, consisting of miR-17, miR-18a, miR-19a, miR-19b, miR-
20a and miR-92. This cluster is known to act as an oncogene (116) and has been shown 
to be involved in enhanced cell proliferation and suppression of apoptosis in human B-
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cell lymphomas and in colon cancer cells (66, 116). The strong downregulation of this 
cluster may contribute to the complex pathway in which ERβ generates the 
antiproliferative effect, as demonstrated in the xenograft study (112). We identified and 
confirmed that the ERβ regulated genes CLU and NCOA3 (SRC-3) both were induced 
when miR-17 was silenced. NCOA3 is reported to affect the expression of other 
transcription factors and regulators such as NCOA1 (SRC-1), AHR, PPARG, CEBPD 
and MYB. These genes were all changed in ERβ-expressing cells, pointing towards an 
ERβ-driven regulation of these genes partially through the downregulation of miR-17 
and the subsequent upregulation of NCOA3. NCOA3 is a nuclear receptor coactivator, 
affecting the transcriptional activity of both ERα and ERβ (156, 254). NCOA3 has been 
associated with a more locally advanced disease in CRC, and elevated levels of the 
protein have been reported in many different cancers (258) (99).  However, elevated 
levels of NCOA3 have also been found to be associated with a better overall survival in 
CRC (99). Therefore, the role of NCOA3 as an ERβ coregulator and the upregulatory 
effect of ERβ regulated miRNAs on NCOA3 in colon cancer needs to be explored 
further.  
 
We also found that treatment with cisplatin, a DNA damaging agent, led to a higher cell 
death in miR-17 silenced cells compared to wild type cells. This finding indicates an 
interesting role for co-treatment with miR-17 inhibitor and chemotherapy in colon 
cancer patients resistant to chemotherapy.  
  
In conclusion, we have shown that stable re-expression of ERβ in SW480 colon cancer 
cells resulted in a large change of the miRNA pool. To our knowledge, this is the first 
report of ERβ affecting miRNAs. We further detected changed mRNA levels of many 
miRNA predicted target genes, illustrating the impact of the ERβ regulated miRNA 
pool on mRNA levels. 
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
ERα was discovered more than 50 years ago and major efforts have been put into 
describing the molecular network by which it works. The regulatory networks of ERα 
are therefore relatively well studied, and ERα is used as a therapeutic target in breast 
cancer. ERβ was discovered 15 years ago, and the molecular mechanisms behind ERβ‟s 
effect are still far from clear. Normal breast epithelia expresses both ERα and ERβ, but 
the ratio between them changes during cancer progression. A standard procedure in 
breast cancer diagnostics consists of identifying those patients expressing ERα, thereby 
more likely to respond to tamoxifen treatment. At this time, ERβ is not used in 
diagnostics, and the clinical significance of ERβ in breast cancer has not been 
established. Clinical trials with progestin-estrogen HRT indicate a protective role 
against colorectal carcinoma. As ERβ is the predominant ER in the colonic epithelium 
and is lost during cancer progression, it is reasonable to assume that these protective 
effects are conveyed by ERβ. This has further been supported in vivo studies where 
deletion of ERβ in mice that spontaneously develops intestinal adenomas leads to an 
increase both in size and number of adenomas (94). Despite these facts, the role of ERβ 
in colon cancer is not well explored.  
 
Since ERα has been shown to be involved in the development and progression of breast 
cancer, and ERβ has been indicated to mediate a protective effect in colon cancer, it is 
of importance to elucidate the molecular mechanism behind their tumorigenic and anti-
tumorigenic properties, respectively. The aim of this thesis was to dissect the regulatory 
networks of ERα and ERβ and thereby gain a better knowledge of the molecular and 
cellular mechanisms of estrogen signaling in breast and colon cancer. A better 
understanding of the regulatory networks by which ERα and ERβ work, would not only 
aid in development of novel therapeutics based on downstream targets of the ER 
pathways but also help identify those patients that might benefit from treatment aiming 
at ERα and/or ERβ. 
 
When this study was initiated, it had been established that ERα was proliferative. It had 
been suggested that ERβ was antiproliferative, but this notion had not yet been widely 
accepted. We could show that ERβ often opposed the transcriptional effect of ERα at 
the transcription levels in T47D cells, especially for genes within proliferation and 
regulation of cell cycle. We also found a set of genes regulated by ERβ alone, 
indicating that in spite of the high homology in their DBDs, there are differences in 
their transcriptional targets. The significance of ERβ in breast cancer has been debated, 
but our data implies that ERβ may play an important role in the treatment and 
diagnostics of breast cancer. Stimulation of ERβ through ERβ specific agonists is one 
future direction for the treatment of estrogen responsive breast cancers. However, it is 
not established to what extent ERβ is expressed in breast cancer tumors due to the 
varying specificity and efficiency of commercially available ERβ antibodies. Therefore, 
there is a need for development of new ERβ antibodies with a better specificity. This 
would facilitate further exploration of ERβ occurrence in breast cancer tumors and lead 
to a better knowledge if ERβ is expressed at those levels that ERβ targeting therapies 
would be beneficial as an alternative treatment method. 
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Most studies on ERβ so far had been performed in cell lines expressing endogenously 
ERα in addition to the transduced ERβ. Therefore, they could only detect how ERβ 
behaved in combination with ERα. We demonstrated that ERβ not only is 
antiproliferative when co-expressed with ERα in breast cancer, but also by itself in 
colon cancer cells. We further showed that this also was true in vivo with xenograft 
ERβ-expressing tumors. Our studies substantially contribute to a better understanding 
of the mechanism behind ERβ‟s antiproliferative effect in colon cancer cells by the 
discovery that ERβ halts the cells in G1-phase through the strong regulatory inhibition 
on MYC and several other cell cycle genes.   
 
ERα has been widely studied, and there are several accepted estrogen target genes. 
However, no transcriptional profile had been established and accepted for ERβ. To 
further explore the impact of ERβ regulation in colon cancer, we performed genome-
wide analyses. This showed that ERβ is capable of regulating a large set of genes 
independently of ERα, and that the set of ERβ regulated genes is cell type and cell line 
specific. We therefore could not establish one specific ERβ transcriptional profile in 
colon cancer cells. However, the different sets of ERβ regulated genes in three different 
colon cancer cell lines were all involved in similar biological processes, such as 
regulation of cell cycle, kinase activity and apoptosis. We therefore suggest that ERβ 
regulates similar biological processes in different cells, but uses different pathways and 
genes to reach them. The exact mechanism behind ERβ‟s regulatory network in colon 
cancer cells is still not clear, but some key factors such as regulation of cell cycle, 
MAKP signaling and PROX1 play important roles. The biological role of these target 
genes in the development and progression of colon cancer as well as correlation 
between them and ERβ expression should be further explored in normal colon cells. In 
addition, for a full understanding of the ERβ regulatory pathways, future studies should 
include a thorough analysis of ERβ binding sites in colon cells, such as with RNAseq 
and ChIP-Seq, as well as proteomic studies and analysis of post-translational 
modifications, especially involving ERβ regulation on kinases and subsequent effect on 
protein phosphorylations.  
 
The finding of gene inhibition by miRNAs is rather new in the field of gene regulation. 
As the number of known miRNAs increases for each year, the understanding of their 
role in different biological pathways and processes is improved. miRNAs are involved 
in most biological processes and are often deregulated in both breast and colon cancer. 
One recent study showed that expression of the mir302/367 cluster efficiently could 
reprogram human and mouse fibroblasts to an induced pluripotent stem cell state (12). 
This demonstrates that changes in the miRNA pool of just a few miRNAs might be 
sufficient for a cell to switch into a different type of cell, or possibly turn cancerous. 
Identification of miRNAs that are associated with normal or disrupted estrogen 
signaling would be of great importance for prognosis and diagnosis. Previous studies 
on ERα regulation of miRNAs in breast cancer cells revealed conflicting results. We 
could show a strong estrogen activated ERα transcriptional response in T47D cells, but 
we did not detect any rapid changes of mature miRNA expression. However, we found 
that stable re-expression of ERβ in colon cancer cells led to a significant change of the 
miRNA pool. Many of the changed miRNAs were indirectly regulated via MYC, but 
others had an ERβ binding site within 100kb indicating a possible direct ERβ 
regulation. This finding offers insight into the long term effect of ERβ activation in 
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colon. In addition, we could show that genes regulated by ERβ could be enhanced 
through ERβ regulated miRNAs, illustrating how ERβ can fine tune gene expression 
through the regulation of miRNAs. To our knowledge, this is the first study presenting 
miRNAs regulated by ERβ. This opens up for an entirely new field of potential 
therapeutic targets of ERβ signaling in colon cancer. Future mimic and inhibitor 
studies, in vitro and in vivo, with detected changed miRNAs are interesting approaches 
to further explore miRNAs as potential therapeutic targets in estrogen dependent colon 
cancers.  
 
The findings in this thesis significantly contribute to elucidating the regulatory 
pathways of the two estrogen receptors. We now know, e.g., that ERβ not only opposes 
the effect of ERα but also induces transcriptional response as a homodimer, that ERβ is 
antiproliferative in both breast and colon cancer cells, partly through ERβ-induced 
inhibition of PROX1, MYC and other G1-phase cell cycle genes, that ERβ may fine-
tune mRNA expression through the regulation of miRNAs and that ERβ has anti-
inflammatory properties. All this supports the notion that ERβ is a potential target in 
breast and colon cancer prevention and/or inflammation proceeding CRC development. 
ERβ expression might be lost in many cancers especially at later stages, thus not a 
possible target for novel therapeutics. One approach would be reintroduction of ERβ in 
these tumors. However, this is currently not a practical or realistic solution. Instead, 
investigations should be done to explore if specific ERβ agonists have treatment 
potential or if novel therapeutics could be aimed at targets downstream of ERβ, such as 
those discovered in this thesis.  
 
Only a few studies have explored the use of ERβ specific ligands or phytoestrogens in 
animal studies, and just one small pilot study has explored the combinatory effect of 
two phytoestrogens on CRC in humans. Given that we have shown that ERβ exhibits 
an antiproliferative effect we suggest that a specific ERβ agonist might prove to be an 
interesting complement in future therapies against early stages of ERβ-expressing 
breast and colon cancer tumors as well as in treatment of inflammation. In addition, 
ERβ specific agonists may potentially be used as a preventive approach for persons 
with an increased risk of developing CRC, such as IBD patients. Undoubtedly, there is 
a need for development and characterization of ERβ specific ligands to be used in vitro 
and in subsequent in vivo randomized clinical trials to fully understand and utilize the 
clinical significance of ERβ in estrogen responsive cancer.  
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